Annotation Detail

Information

Associated Genes: KRAS
Associated Variants: KRAS MUTATION
KRAS MUTATION
Associated Disease: lung non-small cell carcinoma
Source Database: CIViC Evidence
Description: This phase I/Ib two-part study evaluated trametinib in combination with anticancer agents docetaxel or pemetrexed in NSCLC with and without KRAS mutations. Confirmed partial response (PR) was observed in 21% (10/47) patients receiving trametinib/docetaxel. The ORR was 18% (4 PR in 22 patients) in KRAS wild-type versus 24% (six PR in 25 patients) in KRAS-mutant NSCLC. Of the 42 patients treated with trametinib/pemetrexed, 14% (6/42) had a PR; the ORR was 17% (4/23) in KRAS-mutated NSCLC versus 11% (2/19) in KRAS wild-type NSCLC.
Variant Origin: somatic
Variant Origin: Somatic
Evidence URL: https://civic.genome.wustl.edu/links/evidence_items/4862
Gene URL: https://civic.genome.wustl.edu/links/genes/30
Variant URL: https://civic.genome.wustl.edu/links/variants/336
Rating: 3
Evidence Type: Predictive
Disease: Lung Non-small Cell Carcinoma
Evidence Direction: Supports
Drug: Pemetrexed,Docetaxel,Trametinib
Evidence Level: B
Clinical Significance: Sensitivity/Response
Pubmed: 27876675

Drugs